Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 3 4Phase 2 2Phase NA 1Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Advanced Breast Cancer 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Moxifloxacin × Clear all
NCT03405168 2018-11-16

Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer

Sun Yat-sen University

Phase 2 Completed
35 enrolled
Breast

Advanced Breast Cancer

NCT01017731 2015-06-10

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Eli Lilly and Company

Phase 2 Completed
68 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡